Metabolic syndrome in chronic obstructive pulmonary disease

M. D. Majeed Pasha, Shivalingaswamy Salimath, Mohan Rao K. N., Gayathri Devi H. J., Anshum Aneja, Mantha Satya Padmaja, Sujith Halappa


Background: COPD (Chronic obstructive pulmonary disease) is considered as a systemic disease due to associated systemic inflammation which can manifest as metabolic syndrome or its component illnesses. This study was undertaken to determine the proportion of metabolic syndrome in patients with COPD.

Methods: 51 patients with COPD were compared with equal number of age and gender matched controls. GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria were used for diagnosing COPD. Metabolic Syndrome (MS) was diagnosed based on modified NCEP:ATP III criteria (National cholesterol education Program Adult Treatment Panel III). Subjects were evaluated for hypertension, WC, FBS, and serum triglycerides and serum HDL (High-density lipoprotein) to diagnose MS.

Results: Metabolic syndrome was diagnosed in 16 (31.4%) patients with COPD and in 8 (15.7%) controls. The proportion of individual parameters of MS in cases and controls was as follows: DM in 19 (37.3%) cases and 13 (25.5%) controls, hypertension in 21(41.2%) cases and 9 (17.6%) controls, low serum HDL in 31 (60.7%) cases and 22 (43.1%) controls increased WC in 14 (27.5%) cases and 7 (13.7%) controls and elevated serum TG in 12 (23.5%) cases and an equal number of controls.

Conclusions: Metabolic syndrome and its parameters are more prevalent in COPD patients. Early detection and treatment of MS in COPD patients can prevent development of complications due to the combined effects of both diseases.


Body Mass Index, Chemo attractant protein, COPD, Forced expiratory volume in one second, Forced vital capacity, GOLD, HDL, MS, NCEP: ATP III

Full Text:



Global strategy for diagnosis management and prevention of COPD. 2014. Available at

Mason JR, Broaddus C, Martin R, Murry JE. Textbook of respiratory medicine. 5th ed. Saunders Elsevier. 2016;1:116-7.

Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eu Resp J. 2003;21(2):347-60.

Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eu Resp J. 2008;32:962-9.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement - Executive summary. Critical Pathways Cardiol. 2005;4(4):198-203.

Watz H, Waschki B, Kristen A. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136:1039-46.

Lam KBH, Jordan RE, Jiang CQ, Lam et al. Airflow obstruction and metabolic syndrome: the Guangzhou biobank cohort study. Eu Resp J. 2010;35:317-23.

Petty TL. The history of COPD. Int J Chronic Obstructive Pulm Dis. 2006;1(1):3.

Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):104S-15S.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. Intern Med. 2010;49(19):2093-9.

Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139:165-73.

De Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Bellón-Cano JM, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012;7:679-86.

Niranjan MR, Dadapeer K, Rashmi K. Lipoprotein profile in patients with chronic obstructive pulmonary disease in a tertiary care hospital in South India. J Clin Diagn Res. 2011;5:990-3.

Fabbri LM, Luppi F, Beghe B. Complex chronic comorbidities of COPD. Eur Resp J. 2008;31:204-12.

Van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J. 2000;15:915-21.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.

Almagro P, García LF, Cabrera F, Montero L, Morchón D, Díez J, Soriano J, Epoc Group of the Spanish Society of Internal Medicine. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. Respir Med. 2010;104(2):253-9.

Mannino DM, Thorn D, Swensen A. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-9.

Lone N, Courbon D, Thomas F. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179:509-16.